4,5-Dichlor-2-methylanisol | 37420-51-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4,5-Dichlor-2-methylanisol
• 英文别名: 4,5-Dichloro-2-methylanisole；1,2-dichloro-4-methoxy-5-methylbenzene
• CAS: 37420-51-2
• 化学式: C₈H₈Cl₂O
• mdl: MFCD18441759
• 分子量: 191.057
• InChiKey: AYBNATFYSUGYSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY<br/>[FR] ATROPISOMÉRISME POUR UNE SÉLECTIVITÉ AMÉLIORÉE DES INHIBITEURS DE KINASE
  申请人：SAN DIEGO STATE UNIV RESEARCH FOUNDATION

  公开号：WO2018237134A1

  公开（公告）日：2018-12-27

  The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds. The compounds herein are atropisomers having increased kinase selectivity, and are for use in treating conditions that benefit from selective kinase inhibition.

  这项发明提供了一系列构象稳定且选择性激酶抑制剂，以及使用这些激酶抑制剂的方法。评估了扭曲异构体对激酶选择性的影响，发现与快速相互转化的母体化合物相比，选择性得到了改善。本文中的化合物是具有增强激酶选择性的扭曲异构体，用于治疗受益于选择性激酶抑制的疾病。
• [EN] CXCR3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR CXCR3
  申请人：CELGENE INT II SARL

  公开号：WO2018045246A1

  公开（公告）日：2018-03-08

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  提供具有以下式I结构的化合物：其中R、R1、R2、R3a和R3b如本文所述定义。还提供了包含这些化合物的药物组合物，以及与它们的制造和使用相关的方法。
• Isoquinoline inhibitors of P38
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2036891A2

  公开（公告）日：2009-03-18

  The present invention relates to inhibitors (ia)-(id) of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders. All substituents are as in claim 1.

  本发明涉及 p38 抑制剂 (ia)-(id)，p38 是一种哺乳动物蛋白激酶，参与细胞增殖、细胞死亡和对细胞外刺激的反应。本发明还涉及生产这些抑制剂的方法。本发明还提供了包含本发明抑制剂的药物组合物以及利用这些组合物治疗和预防各种疾病的方法。所有取代基与权利要求1中的相同。
• Heterocyclic inhibitors of p38
  申请人：Vertex Pharmceuticals Incorporated

  公开号：EP2062879A1

  公开（公告）日：2009-05-27

  The present invention relates to inhibitors of p38, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

  本发明涉及 p38 抑制剂，p38 是一种哺乳动物蛋白激酶，参与细胞增殖、细胞死亡和对细胞外刺激的反应。本发明还涉及生产这些抑制剂的方法。本发明还提供了包含本发明抑制剂的药物组合物以及利用这些组合物治疗和预防各种疾病的方法。
• CXCR3 receptor agonists
  申请人：RECEPTOS LLC

  公开号：US11040954B1

  公开（公告）日：2021-06-22

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  所提供的化合物具有下式 I 的结构： 其中 R、R1、R2、R3a 和 R3b 如本文所定义。此外，还提供了包含此类化合物的药物组合物，以及与其制造和使用相关的方法。